keep the price down so handlers can cover. Just a line item on the budget.
MIght still have some IP, but most of it was sold. Look at the SEC filings to see what was sold off. I think Denge was one of them.
anybody have last weeks count?
The numbers indicate that the big problem with sales has been that new prescriptions did not translate into refills. The obvious reason is insurance coverage. Carriers adopt the posture of medicare, i.e. that treatment must be deemed medically necessary. With nothing but a non-inferiority designation the only rationale for prescribing is needle aversion. if the claim of faster action, matching sugar rise after a meal is substantiated, it paves the way for coverage. Coupled with documented proof that IT is less likely to cause hypoglycemia, the drug will sell.
Eteplirsen trial is hardly a failure. 10 boys walking after 5 years. And it's taken nearly 10 years. The reason you're impatiient is that buyout rumors based on similar acquisitions ran up CEMP price unrealistically.
That's near resistance. also a triple top. Hope it holds and consolidates. Low volume for a sustainable rally. All based on technical analysis, fwiw. The major correlation with news is what impresses me. In every recent case the direction in the days and weeks before news has telegraphed the move.
62 million price increase, 20 million for milestone. roughly 20 million to go. With the milestone deal I think an outside investor might loan the 20 million against the holdback.
I'm confused. Does this mean the study is unblinded and in the open label extension or are the symptoms telling that he is in the treatment arm ( like Max and the juice box ).
good stuff. Metformin was enough to help me lose weight and get fasting BS well under 100.
Agree more research is needed to see whether Afrezza is better than short acting injectables in this context. Certainly it is more acceptable than injecting. When I researched this basal insulin was found to be superior to prandial. But that may well be due to the inferior PK of glargine and lispro.
True. I don't disagree with the premise of the post. But Afrezza won't cure prediabetes by itself. The SOC for prediabetes is diet and exercise and a low dose of metformin. Little is known about the MOA of metformin. The argument I have for using Aftzza instead of metformin as an adjunct to diet and exercise is that it is a well known human-derived substance. It is unclear to me how Afrezza would affect the primary concern in prediabetes, i.e. gluconeogenesis. Insulin has two modes of action. It stimulates the liver to liberate sugar and it stimulates the liver and other tissues to take up sugar. The problem is the level of insulin needed to main the balance between these two actions (homeostasis) gets shifted upwards.
That's a stretch. Prediabetics need to increase their insulin sensitivity and alter their metabolism to use energy instead of storing it.